A study of NSCLC found that tumors treated with short-term VEGFR TKIs had reduced levels of MET compared with sensitive tumors, while MET was up-regulated in tumors that progressed on long-term treatment, thus making the tumor more refractory to treatment after the initial response stage [45]. This evidence concerns the gene MET and non-small cell lung carcinoma.